BRPI0918844A2 - syngr4 para genes-alvo de terapia e diagnóstico do câncer - Google Patents

syngr4 para genes-alvo de terapia e diagnóstico do câncer

Info

Publication number
BRPI0918844A2
BRPI0918844A2 BRPI0918844A BRPI0918844A BRPI0918844A2 BR PI0918844 A2 BRPI0918844 A2 BR PI0918844A2 BR PI0918844 A BRPI0918844 A BR PI0918844A BR PI0918844 A BRPI0918844 A BR PI0918844A BR PI0918844 A2 BRPI0918844 A2 BR PI0918844A2
Authority
BR
Brazil
Prior art keywords
syngr4
target genes
cancer diagnosis
therapy target
therapy
Prior art date
Application number
BRPI0918844A
Other languages
English (en)
Inventor
Akira Togashi
Yataro Daigo
Yusuke Nakamura
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BRPI0918844A2 publication Critical patent/BRPI0918844A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI0918844A 2008-08-27 2009-08-24 syngr4 para genes-alvo de terapia e diagnóstico do câncer BRPI0918844A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19035808P 2008-08-27 2008-08-27
PCT/JP2009/004059 WO2010023866A1 (en) 2008-08-27 2009-08-24 Syngr4 for target genes of cancer therapy and diagnosis

Publications (1)

Publication Number Publication Date
BRPI0918844A2 true BRPI0918844A2 (pt) 2015-12-08

Family

ID=41721049

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918844A BRPI0918844A2 (pt) 2008-08-27 2009-08-24 syngr4 para genes-alvo de terapia e diagnóstico do câncer

Country Status (9)

Country Link
US (1) US20110262463A1 (pt)
EP (1) EP2350276A4 (pt)
JP (1) JP2012501161A (pt)
KR (1) KR20110063490A (pt)
CN (1) CN102203250A (pt)
BR (1) BRPI0918844A2 (pt)
CA (1) CA2734979A1 (pt)
RU (1) RU2011111387A (pt)
WO (1) WO2010023866A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105264381B (zh) * 2013-05-16 2018-06-01 国立大学法人京都大学 用于确定癌症预后的方法
CN103913570B (zh) * 2014-03-24 2016-03-23 张灏 癌症危险分层生物标志物、其应用以及癌症危险分层装置
CN112626118B (zh) * 2020-11-12 2023-06-23 清华-伯克利深圳学院筹备办公室 细胞株及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003260966A1 (en) * 2002-09-30 2004-04-23 Japan As Represented By The President Of The University Of Tokyo Genes and polypeptides relating to human pancreatic cancers
AU2002344094A1 (en) * 2002-10-16 2004-05-04 Ngk Insulators, Ltd. Human housekeeping genes and human tissue-specific genes
TW200600785A (en) * 2004-03-23 2006-01-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancer
WO2008023840A2 (en) * 2006-08-25 2008-02-28 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer

Also Published As

Publication number Publication date
KR20110063490A (ko) 2011-06-10
US20110262463A1 (en) 2011-10-27
RU2011111387A (ru) 2012-10-10
EP2350276A1 (en) 2011-08-03
WO2010023866A1 (en) 2010-03-04
CA2734979A1 (en) 2010-03-04
CN102203250A (zh) 2011-09-28
JP2012501161A (ja) 2012-01-19
EP2350276A4 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
EP2373794A4 (en) NECTINE-4 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS OF CANCER
BRPI1008566A8 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI1015215A2 (pt) porções de ligação alvo armadas com amatoxina para o tratamento de câncer
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0924549A2 (pt) nano fotomedicamentos como alvo para terapia fotodinâmica do câncer
BRPI0821660A2 (pt) Combinações de agentes terapêuticos para tratamento de câncer
BRPI0906389A2 (pt) Sistema de terapia de pele
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BR112012005594A2 (pt) tratamento de câncer
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI0821248A2 (pt) Inibidores de cinesina como fármacos terapêuticos para câncer
IL218118A0 (en) Target genes for cancer therapy
BRPI1010874A2 (pt) composição para o tratamento de câncer de próstata
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BR112012002797A2 (pt) tratamento de câncer de próstata
DK2219683T3 (da) Målrettet radioterapi
EP2342568A4 (en) CADHERIN-17 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET FOR LIVER CANCER
EP2329044A4 (en) PRMT1 FOR TARGET GENES FOR THE TREATMENT AND DIAGNOSIS OF CANCER
BRPI0922884A2 (pt) compostos para tratamento de câncer
EP2340851A4 (en) DIAGNOSTIC METHOD AND THERAPEUTIC METHOD FOR CANCER
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
BRPI0920743A2 (pt) ribonucleases terapeuticas

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]